Skip links

From Dearth to Discovery: How Gen-AI Supercharges Modern Anomaly Detection

Jump To Section

Anomaly detection using generative AI

Today, advanced Artificial Intelligence has become a prerequisite for making informed business decisions. As companies scale and embrace newer technologies, data volumes grow exponentially. Within this climate, running a sustainable business requires meticulous attention to detail with very little room for error. Thus, robust anomaly detection quickly becomes critical to navigating the complexities of modern business.

Need for Robust Anomaly Detection 

The ACFE reports that organizations are losing ~5% of their annual revenues to fraud, amounting to billions of dollars. In fact, according to the FTC, organizations have lost $10 billion due to fraudulent scams in 2023, compared to $8.8 billion in 2022. It’s a problem plaguing businesses regardless of scale and turnover. Considering the circumstances, it would be rather naive to assume that existing systems, which excel at routine decision-making, can handle these one-offs.

Fraud detection and mitigation is a primary area of application for any anomaly detection engine (ADE), but the breadth of its applications are limited only by one’s imagination. Despite organizations’ concerted efforts, obtaining reliable data, essential for such systems, remains challenging. 

Enriching The Real With Synthetic

The effectiveness of any ADE relies heavily on the data at hand. Organizations frequently find themselves lacking a comprehensive dataset, often with insufficient coverage to address edge cases – a persistent challenge within the industry. Thus, the exercise of anomaly detection in such scenarios devolves into a futile, almost-Sisyphean endeavor.

However, Generative AI’s rise to fame provides a potential solution. It allows the opportunity to enrich organic data via synthetic means. This has been at the core of our efforts in creating our Synthetic Data Generator (SDG) – a Generative AI-based tool that augments real data with synthetic data based on the patterns available. SDG can even account for scenarios beyond the original data’s scope – think zero-day exploits, or frauds that exploit technology yet to be discovered. In cases where real data is unavailable, it uses multiple Gen AI algorithms with user-defined schema/metadata to generate fresh synthetic data. Customers have been asking for time series data generation and forward/backward period-data generation so they can conduct thorough trend analysis and forecasting. SDG does all this effortlessly. 

GenAI Powered Anomaly Detection 

Once the data problem has been solved synthetically, organizations need an ADE that seamlessly integrates with pre-existing stacks and keeps up with the dynamic nature of modern businesses. That’s where GADE (Generic Anomaly Detection Engine) comes into play – a comprehensive industry-agnostic ADE that reduces time-to-market significantly. 

  • GADE identifies new classes of anomalies by leveraging Generative AI and an ensemble of both supervised and unsupervised algorithms. 
  • It predicts future anomalies and classifies them by severity – meaning business owners need not worry about being blindsided by unexpected disruptions.
  • Moreover, it proactively alerts them to potential issues and prioritizes them based on their impact, allowing for timely and informed decision-making.

GADE is a fully customizable accelerator with applications across industries – from financial fraud to health tracking to manufacturing defect prediction. 

Also read: AI Augments and Human Intelligence: An Evolution

The Panacea: SDG + GADE 

The synergy between SDG and GADE extends beyond data generation; it represents a symbiotic relationship aimed at continuously enhancing anomaly detection processes and fortifying preparedness for edge cases. SDG’s ability to generate synthetic data that mirrors real-world trends and patterns serves as invaluable input for GADE. As GADE processes and analyzes this synthetic data, it refines its algorithms and strengthens its anomaly detection capabilities. This iterative process ensures that GADE remains adaptive and resilient in identifying emerging anomalies, thereby empowering organizations with heightened vigilance and proactive decision-making.

The marriage of Generative AI and anomaly detection represents a paradigm shift in how organizations approach data-driven decision-making. By harnessing the power of AI to generate synthetic data, businesses can overcome the limitations of traditional data sources and achieve unprecedented levels of accuracy and reliability in anomaly detection. As we continue to push the boundaries of what is possible with AI, the potential for innovation in anomaly detection and beyond is limitless. 

Picture of Iqbal Ahmad

Iqbal Ahmad

Latest Reads


Suggested Reading

Ready to Unlock Your Enterprise's Full Potential?

Adaptive Clinical Trial Designs: Modify trials based on interim results for faster identification of effective drugs.Identify effective drugs faster with data analytics and machine learning algorithms to analyze interim trial results and modify.
Real-World Evidence (RWE) Integration: Supplement trial data with real-world insights for drug effectiveness and safety.Supplement trial data with real-world insights for drug effectiveness and safety.
Biomarker Identification and Validation: Validate biomarkers predicting treatment response for targeted therapies.Utilize bioinformatics and computational biology to validate biomarkers predicting treatment response for targeted therapies.
Collaborative Clinical Research Networks: Establish networks for better patient recruitment and data sharing.Leverage cloud-based platforms and collaborative software to establish networks for better patient recruitment and data sharing.
Master Protocols and Basket Trials: Evaluate multiple drugs in one trial for efficient drug development.Implement electronic data capture systems and digital platforms to efficiently manage and evaluate multiple drugs or drug combinations within a single trial, enabling more streamlined drug development
Remote and Decentralized Trials: Embrace virtual trials for broader patient participation.Embrace telemedicine, virtual monitoring, and digital health tools to conduct remote and decentralized trials, allowing patients to participate from home and reducing the need for frequent in-person visits
Patient-Centric Trials: Design trials with patient needs in mind for better recruitment and retention.Develop patient-centric mobile apps and web portals that provide trial information, virtual support groups, and patient-reported outcome tracking to enhance patient engagement, recruitment, and retention
Regulatory Engagement and Expedited Review Pathways: Engage regulators early for faster approvals.Utilize digital communication tools to engage regulatory agencies early in the drug development process, enabling faster feedback and exploration of expedited review pathways for accelerated approvals
Companion Diagnostics Development: Develop diagnostics for targeted recruitment and personalized treatment.Implement bioinformatics and genomics technologies to develop companion diagnostics that can identify patient subpopulations likely to benefit from the drug, aiding in targeted recruitment and personalized treatment
Data Standardization and Interoperability: Ensure seamless data exchange among research sites.Utilize interoperable electronic health record systems and health data standards to ensure seamless data exchange among different research sites, promoting efficient data aggregation and analysis
Use of AI and Predictive Analytics: Apply AI for drug candidate identification and data analysis.Leverage AI algorithms and predictive analytics to analyze large datasets, identify potential drug candidates, optimize trial designs, and predict treatment outcomes, accelerating the drug development process
R&D Investments: Improve the drug or expand indicationsUtilize computational modelling and simulation techniques to accelerate drug discovery and optimize drug development processes